Endometriosis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Endometriosis is defined as the abnormal growth of endometrial tissue, which is similar to that which lines the interior of the uterus but occurs outside of the uterus. During menstruation, endometrial tissue is shed. Endometrial implants are areas of endometrial tissue found in ectopic sites. These lesions are most generally found on the ovaries, the Fallopian Tubes, the uterine surface, the bowel, and the pelvic cavity membrane lining (i.e., the peritoneum). They are less frequently found in the vaginal, cervix, and bladder. Endometriosis can occur outside the pelvis on rare occasions. While endometrial implants can cause complications, they are usually harmless. Endometriosis is classified into four stages: I (mild), II (mild), III (moderate), and IV (severe) based on the number, location, and depth of implants, as well as the presence of filmy or dense adhesions. Another staging system is based primarily on the company and severity of pelvic pain. However, a more reliable staging method is being sought because intra-observer and inter-observer variability are high in the staging systems.
The prevalence of cases of Endometriosis
ranges from 350 to 378 cases per 100,000 population in the USA.
The competitive
landscape of Endometriosis includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Endometriosis
across 8 MM market from the center of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Endometriosis
Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data
Inputs with sourcing, Market Event, and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 V-Endo Immunitor LLC Phase 2
2 Leuprolide Enteris
BioPharma Inc. Phase 2
3 BGS649 Mereo
BioPharma Phase 2
4 BOL-DP-o-08 Breath
of Life International Pharma Ltd Phase 2
5 linzagolix tablet ObsEva
SA Phase 3
6 Quinagolide Ferring
Pharmaceuticals Phase 2
7 Relugolix Myovant
Sciences GmbH Phase 3
8 Elagolix AbbVie Phase 3
9 Vaginal Danazol Viramal
Limited Phase 2
Comments
Post a Comment